Repaglinide

An ATP-dependent potassium channel blocker

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
100mg

￥887.00

710.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajci16314
CAS: 135062-02-1
别名: 瑞格列奈; AG-EE 623ZW
分子式: C27H36N2O4
分子量: 452.59
纯度: >98%
溶解度: ≥ 17mg/mL in DMSO, ≥ 16.73 mg/mL in EtOH with ultrasonic
储存: Store at -20°C
库存: 现货

Background

Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus[1].

Repaglinide reduces postprandial glucose levels by enhancing the early phase of insulin secretion and increasing the total amount of insulin secreted[1].

Repaglinide (AG-EE 623ZW) is very rapidly absorbed (tmax less than 1 hour) with a t1/2 of less than one hour. Furthermore, Repaglinide is inactivated in the liver and more than 90 % excreted via the bile. Repaglinide (1 mg/kg p.o.) is effective (P<0.001) as an insulin-releasing agent in a rat model (low-dose streptozotocin) of type 2 diabetes.

参考文献:
[1]. Wang LC, et al. Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus.Medicine (Baltimore). 2018 Sep;97(38):e12476.